SCHEMBL609910

SCHEMBL609910

COc1ccc(CCC(O)c2cccc(OCCNC(=O)OC(C)(C)C)c2)cc1OC

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.52
SMN1; SMN2 Q16637 2/20 0.43
ADRB2 P07550 3/20 0.43
MAPT P10636 2/20 0.43
POLB P06746 1/20 0.43
ADRB1 P08588 2/20 0.42
HTR1A P08908 1/20 0.42
ADRA2C P18825 1/20 0.42
SLC6A4 P31645 1/20 0.42
ADRA1A P35348 1/20 0.42
HTR2B P41595 1/20 0.42
SLC6A3 Q01959 1/20 0.42
KCNH2 Q12809 1/20 0.42
ATM Q13315 1/20 0.42
NR1H3 Q13133 1/20 0.42
KMT2A Q03164 1/20 0.42
KDM4E B2RXH2 1/20 0.42
ADRB3 P13945 1/20 0.41
LMNA P02545 1/20 0.41
PDK2 Q15119 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL609911 1.00 ALDH1A1 (0.52) ALDH1A1SMN1; SMN2ADRB2MAPTPOLB
SCHEMBL13298689 0.89 ALDH1A1 (0.51) ALDH1A1SMN1; SMN2ADRB2MAPTPOLB
SCHEMBL3714122 0.88 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2ADRB2MAPTPOLB
SCHEMBL611592 0.85 ALDH1A1 (0.58) ALDH1A1SMN1; SMN2ADRB2MAPTPOLB
SCHEMBL15049104 0.84 FKBP1A (0.46) ALDH1A1KDM4E
SCHEMBL16158169 0.84 FKBP1A (0.46) ALDH1A1KDM4E
SCHEMBL8403525 0.84 CA12 (0.46) MAPTPDK2CA12CA1CA2
SCHEMBL499106 0.84 FKBP1A (0.46) ALDH1A1KDM4E
SCHEMBL29731126 0.84 FKBP1A (0.46) ALDH1A1KDM4E
SCHEMBL10110962 0.84 CA12 (0.46) MAPTPDK2CA12CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120041019-A1 PROTEASE INHIBITORS AMPLYX PHARMACEUTICALS, INC. 2012-02-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120041019-A1 PROTEASE INHIBITORS SERPINB1, PREP, DNPEP ALDH1A1 2740/4885SMN1; SMN2 2490/4885ADRB2 4834/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.